玻璃体腔注射康柏西普联合递法明片治疗病理性近视脉络膜新生血管的疗效观察  

Clinical observation of intravitreal injection of conbercept combined with difrarel in the treatment of choroidal neovascularization in pathologic myopia

作　　者：史志洁 

机构地区：[1]河南省洛阳市第一人民医院眼科,洛阳471000

出　　处：《临床医学》2016年第9期42-44,共3页Clinical Medicine

摘　　要：目的观察玻璃体腔注射康柏西普联合口服递法明片治疗病理性近视脉络膜新生血管(CNV)的临床疗效及安全性。方法回顾性分析病理性近视脉络膜新生血管患者16例(16眼)的临床资料。采用玻璃体腔注射一次初始计量为0.5 mg(0.05 ml)康柏西普眼内注射液(含0.5 mg康柏西普),术后给予患者口服递法明片2个月进行治疗。术后1、3、6个月随访复诊,行最佳矫正视力(BCVA)、荧光素眼底血管造影(FFA)、光学相干断层扫描(OCT)及眼压检查。随访期内若发现仍为活动性CNV或CNV病灶扩大或新病灶出现则行再次注射治疗。结果术后1、3、6个月最佳矫正视力分别为0.28±0.03、0.36±0.03、0.38±0.04,差异有统计学意义(F=21.506,P=0.000);术后1、3、6个月分别与治疗前比较均明显提高,差异有统计学意义(P<0.05)。术后1、3、6个月的黄斑中心凹视网膜厚度分别为261.0±8.56、233.9±6.71、229.0±5.80,差异有统计学意义(F=286.28,P=0.000);术后1、3、6个月分别与治疗前比较均明显降低,差异有统计学意义(P<0.05)。术后6个月随访时FFA检查结果示15眼CNV完全闭合,1眼CNV大部分闭合。随访期内10眼行1次玻璃体腔注射治疗,5眼行2次玻璃体腔注射治疗,1眼行3次玻璃体腔注射治疗,平均注射次数1.43次;随访期内玻璃体腔注射后未出现高眼压症状。随访期间,所有患者未发生严重眼部及全身严重并发症。结论玻璃体腔注射康柏西普联合口服递法明片治疗病理性近视脉络膜新生血管是安全、有效的治疗方法。Objective To observe the clinical effect and safety of intravitreal injection of conbercept combined with difrarel in the treatment of ehoroidal neovascularization in pathologic myopia. Methods The clinical records of 16 patients（ 16 eyes） with ehoroidal neovascularization in pathologic myopia were retrospectively reviewed. All patients were treated by intravitreal injection of cbonbercept 0. 5 mg（0. 05 ml） as the first initial measurement, and oral difrarel were used for 2 months after injection. BCVA, FFA, OCT and intraoeular pressure were observed 1 month,3 months ,6 montha after operation. During the follow-up period, intravitreal injection of eonbereept was performed again if active CNV or CNV expansion or new CNV were observed. Results The best corrected visual acuity after intravitreal injection in 1 month, 3 months, 6 months were respectively 0. 28 ± 0. 03, 0. 36 ± 0.03, 0. 38 ± 0. 04, there were statistically significant differences （ F = 21. 506, P = 0. 000 ） ; There were significantly improved in 1 month, 3 months, 6 months compared with before treatment（P 〈 0. 05 ）. The central macular retinal thickness after intravitreal injection in 1 month, 3 months, 6 months were respectively 261.0 ± 8.56, 233.9 ± 6. 71, 229. 0 ± 5.80, there were statistically significant differences （ F = 286. 28, P = 0. 000 ） ; There were significantly decreased in 1 month, 3 months, 6 months compared with before treatment（P 〈 0. 05 ）. After 6 months, FFA examination results showed that the CNV was completely closed in 15 eyes, and most closed in 1 eye. During the follow-up period, 10 eyes were treated with 1 time, 5 eyes were treated with 2 times of intravitreal injection, 1 eye were treated with 3 times of intravitreal injection, the average injection times was 1.43 times ; during the follow-up period, there was no high intraoeular pressure after intravitreal injection. All patients did not have severe ocular and systemic complications. Conclusion Intravitreal injection of conbereept combined

关 键 词：康柏西普 递法明 病理性近视 脉络膜新生血管 

分 类 号：R773.4[医药卫生—眼科]